NCT04993625

Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study

Selective Avoidanve of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm Study

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 178 (estimated)
• Sponsor: Jeong Eon Lee · Academic / Other
• Sex: Female
• Age: 20 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when physical examination expected complete remission. And radiological expected Tumor size ≤ 2cm or non-mass enhancement ≤ 4cm.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
PROCEDURE	avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy	Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla

Timeline

• Start date: 2021-09-27
• Primary completion: 2028-12-31
• Completion: 2028-12-31
• First posted: 2021-08-06
• Last updated: 2024-01-26

Locations

1 site across 1 country: South Korea